The Steadfast Group Ltd (ASX: SDF) share price is in focus today following an update on a non-binding indicative proposal, with a further four-week exclusivity period now in place as Amwins Group and Dragoneer Investment Group progress their offer of $6.00 per share in cash.

What did Steadfast Group report?

• Consortium has re-confirmed its intention to acquire Steadfast at $6.00 per share in cash.
• Soft exclusivity period extended by four weeks under the Process Deed.
• Proposal made via a scheme of arrangement for 100% of Steadfast’s outstanding shares.
• No binding agreement reached at this stage; deal remains non-binding and indicative.

What else do investors need to know?

The Steadfast Board notes there is no guarantee a binding agreement will be reached and urges shareholders there is no certainty the proposal will result in a formal transaction. Shareholders do not need to take any action at this time.

The group will keep the market informed as new details emerge. Steadfast continues to operate its extensive insurance broker and agency networks across Australia, New Zealand, Singapore, and the USA, serving a broad client base in the insurance sector.

What’s next for Steadfast Group?

Steadfast will continue cooperating with the consortium during the extended exclusivity period. The company’s board is carefully considering the interests of all shareholders in relation to the proposal.

Management has reiterated that further updates will be provided to the market as appropriate, keeping investors informed on any material developments as the process unfolds.

Steadfast Group share price snapshot

Over the past 12 months, Steadfast shares have declined 13%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Steadfast Group extends exclusivity on $6.00 per share takeover offer appeared first on The Motley Fool Australia.

More reading

• Fletcher Building lifts FY26 profit guidance as quarterly volumes rise
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• Why the ASX 200 is sliding towards a 4-week low today
• Qube shares: Scheme now effective and special dividend declared

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Steadfast Group. The Motley Fool Australia has positions in and has recommended Steadfast Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

$60,000 per year in passive income from ASX dividend shares sits comfortably above ASFA’s modest retirement standard and within reach of the comfortable retirement benchmark for a single person.

The maths is straightforward.

To generate $60,000 per year in dividend income at an average yield of 5%, you need approximately $1.2 million invested.

At a 6% yield, you need $1 million.

Three ASX dividend shares offer different but complementary ways to build toward that target.

Telstra: the defensive anchor

Telstra Group Ltd (ASX: TLS) is the natural starting point for any ASX passive income portfolio.

Not because it offers the highest yield, but because it offers reliability.

Telstra has not cut its dividend since 2019 and has increased its annual payout every year since 2022.

CommSec consensus estimates point to a fully franked dividend of 21 cents per share in FY26, rising to 21.5 cents in FY27.

At $4.92 per share, that implies a forward yield of approximately 4.3%, or a grossed-up yield of approximately 6.1% including franking credits.

That franked income is particularly powerful inside superannuation, where franking credits arrive as cash rather than being absorbed by tax.

A $400,000 investment in Telstra at a 5.86% grossed-up yield generates approximately $23,440 per year.

Suncorp: the recovery play with a growing payout

Suncorp Group Ltd (ASX: SUN) had a difficult FY26.

Catastrophe costs ran to approximately $580 million above budget and weighing on near-term dividends.

Despite this, UBS forecasts a fully franked annual dividend of 66 cents per share for FY2026.

This would imply a grossed-up yield of approximately 5.0% at the current share price of $18.94.

The more compelling part for this ASX dividend share is the trajectory.

UBS projects Suncorp’s dividend climbing toward $1.09 per share by FY2030, implying a forward grossed-up yield of approximately 8.2% at today’s price.

That reflects a scenario where FY26’s elevated catastrophe costs are unlikely to repeat at the same scale, and where improving margins support a multi-year dividend recovery.

A $350,000 investment in Suncorp at a 5.0% grossed-up yield generates approximately $17,500 per year today. This should grow materially as the dividend recovers.

Amcor: the quarterly payer

Amcor Plc (ASX: AMC) brings something Telstra and Suncorp do not: quarterly dividends.

Most ASX companies pay twice yearly. Amcor pays four times per year, giving income investors a more frequent and consistent cash flow.

Amcor’s most recently declared quarterly dividend was 91 cents per share in AUD terms. This translates to an annualised payout of approximately A$3.64 per share.

At $63.92 per share, that implies a trailing yield of approximately 5.7%.

Unfortunately, that yield is unfranked, reflecting Amcor’s UK domicile and predominantly offshore earnings.

However, the yield more than compensates for the lack of franking at an absolute level.

The business is delivering too. In Q3 FY26, Amcor delivered net sales of US$5.91 billion, up 77% year-on-year, as Berry Global synergies continued to flow through.

A $320,000 investment in Amcor at 5.7% generates approximately $18,240 per year.

The portfolio maths for these ASX dividend shares

$400,000 in Telstra at 6.1% generates approximately $24,400 per year.

$350,000 in Suncorp at 5.0% generates approximately $17,500 per year.

$320,000 in Amcor at 5.7% generates approximately $18,240 per year.

Combined, a $1,070,000 portfolio across these three stocks generates approximately $60,140 per year, essentially hitting the $60,000 target.

Foolish takeaway

$60,000 in annual passive income from ASX dividend shares is achievable with approximately $1 million to $1.2 million invested across reliable, income-producing businesses.

Telstra provides the defensive anchor with franked income.

Suncorp provides the income growth trajectory.

Amcor provides the quarterly cash flow and global defensive exposure.

Income investors looking for high yield at a reasonable price don’t need to look much further than these three.

The post How to build $60,000 in annual passive income from ASX dividend shares appeared first on The Motley Fool Australia.

More reading

• These ASX shares could generate $10,000 per year in passive income
• Are Telstra shares a buy for passive income?
• How much do I need in my superannuation to get $6,000 per month in passive income?
• How much is needed in superannuation to target a $70,000 annual passive income?
• 5 of the best investments on the ASX right now to complement your superannuation

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Amcor Plc and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) is one of Australia’s greatest corporate success stories.

For decades, the biotech company has built a global business around specialised medical products that solve serious healthcare problems. It has expanded internationally, developed valuable expertise, and become one of the country’s most recognised companies.

But great companies can still go through difficult periods.

Confidence lost

CSL has lost some of the market confidence it once enjoyed, with investors questioning growth expectations, execution, and whether the company can return to its previous level of performance.

The question for investors is whether this is a permanent change or an opportunity created by short-term disappointment.

I think CSL shares are worth buying in July.

A biotech business built on real needs

The reason I continue to like CSL is that its products are connected to genuine medical demand.

The company operates across plasma-derived therapies, vaccines, and specialist healthcare products. These are areas where patients and healthcare systems rely on effective treatments rather than temporary consumer trends.

That creates a different type of growth opportunity.

Healthcare demand tends to be supported by long-term forces such as ageing populations, improving access to treatment, and advances in medical technology.

CSL’s plasma business remains particularly important. Collecting plasma, manufacturing therapies, and supplying patients around the world requires significant infrastructure, expertise, and regulatory capability.

Those advantages have taken decades to build.

I think that is easy to overlook when investors are focused on short-term earnings pressure.

The market has become more cautious

CSL’s recent challenges are real. Investors have raised concerns around the performance of parts of the business, including Vifor, while also assessing the longer-term outlook for vaccines and plasma therapies.

Those concerns deserve attention. However, I think the market may have moved too far in the other direction.

CSL does not need to return to being viewed as a perfect growth company for its shares to perform well. It just needs to stabilise the business, improve execution, and show that its core strengths remain valuable.

That feels achievable to me.

One thing I like about CSL is that it operates in complex markets where experience is important. Competitors cannot simply appear overnight and replicate decades of research, manufacturing capability, regulatory knowledge, and global relationships.

Why this could be an opportunity

When a company with a strong history falls out of favour, investors often have to decide whether the problems are temporary or structural.

With CSL, I think it is a temporary issue and the long-term opportunity remains intact.

The company still operates in markets with significant unmet demand. It still has global scale. And it still has the expertise required to compete in highly specialised healthcare areas.

The recovery may take time. Investors may need patience while management continues improving the business and rebuilding confidence. The share price may not immediately reflect any progress, but I would argue the worst is now behind it.

Foolish takeaway

I think CSL is a fallen ASX giant worth buying in July.

The company has faced genuine challenges, and investors should not ignore them. But I think the strength of CSL’s underlying business, its global position, and the long-term demand for its products make it one of the more interesting recovery opportunities on the ASX.

Sometimes the best investments come from companies that have temporarily lost favour while their long-term advantages remain.

The post Is CSL a fallen ASX giant to buy in July? appeared first on The Motley Fool Australia.

More reading

• The only 3 ASX blue-chip shares I’d buy and hold until 2036
• July is historically one of the best months for ASX shares. Can July FY27 deliver?
• How to tell if an ASX share is cheap or a value trap
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• ASX healthcare shares have jumped 21% since June. Can the recovery continue?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.